Vet Med - Czech, 2017, 62(12):647-653 | DOI: 10.17221/7/2015-VETMED

Changes in regulatory T cells in dogs with B-cell lymphoma and association with clinical tumour stageOriginal Paper

D.S. Baek1, †, T.H. Chung2, †, Y.H. Kim1, S.K. Oh1, K.M. So3, C. Park*,1
1 College of Veterinary Medicine, Chonbuk National University, Jeonbuk, Republic of Korea
2 Department of Animal Science, Joongbu University, Chungnam, Republic of Korea
3 Animal Nutrition and Physiology Team, National Institute of Animal Science, Rural Development and Administration, Jeonbuk, Republic of Korea

Among several mechanisms that allow tumours to disarm the host immune system and thus to evade or suppress protective anti-tumour immunity, an important role for CD4+CD25+FoxP3+ regulatory T cells (Tregs) has emerged. Numerous studies in humans have demonstrated increased Tregs in patients with carcinomas of the breast, lung, and pancreas, and this increased Treg has been correlated with poor prognosis. This study was performed (1) to investigate the percentage of Tregs in total lymphocytes of the peripheral blood in 12 canine patients with B cell lymphoma and (2) to investigate the change in the percentage of Tregs in canine lymphoma of different clinical tumour stages. On the flow cytometric analysis, the relative and absolute numbers of Tregs were significantly increased in 12 canine patients with B-cell lymphoma compared to five healthy beagles included in this study, and the greatest increases in the relative and absolute number of Tregs occurred in two dogs with more advanced World Health Organization clinical stages with bone marrow involvement compared to those in less advanced tumour stages without bone marrow involvement. This study provides basic information regarding the negative role of Treg recruitment in canine lymphoma patients and highlights the potential value of Treg levels as prognostic indicators in canine cancer patients.

Keywords: cancer; regulatory T cell; Treg; canine lymphoma; immune escape; WHO clinical tumour stages

Published: December 31, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Baek DS, Chung TH, Kim YH, Oh SK, So KM, Park C. Changes in regulatory T cells in dogs with B-cell lymphoma and association with clinical tumour stage. Vet Med - Czech. 2017;62(12):647-653. doi: 10.17221/7/2015-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beyer M, Schultze JL (2006): Regulatory T cells in cancer. Blood 108, 804-811. Go to original source... Go to PubMed...
    2. Biller B, Elmslie R, Burnett R, Avery A, Dow S (2007): Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Veterinary Immunology and Immunopathology 116, 69-78. Go to original source... Go to PubMed...
    3. Burnet FM (1971): Immunological surveillance in neoplasia. Immunological Reviews 7, 3-25. Go to original source... Go to PubMed...
    4. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M (2004): Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 10, 942-949. Go to original source... Go to PubMed...
    5. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002): Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology 3, 991-998. Go to original source... Go to PubMed...
    6. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S (1999): Thymus and autoimmunity: Production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. The Journal of Immunology 162, 5317-5326. Go to original source...
    7. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007): Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907. Go to original source... Go to PubMed...
    8. Mukherjee P, Ginardi AR, Madsen CS, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ (2001): MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconjugate Journal 18, 931-942. Go to original source... Go to PubMed...
    9. O'Neill K, Guth A, Biller B, Elmslie R, Dow S (2009): Changes in regulatory T cells in dogs with cancer and associations with tumor type. Journal of Veterinary Internal Medicine 23, 875-881. Go to original source... Go to PubMed...
    10. Quezada SA, Peggs KS, Simpson TR, Allison JP (2011): Shifting the equilibrium in cancer immunoediting: From tumor tolerance to eradication. Immunological Reviews 241, 104-118. Go to original source... Go to PubMed...
    11. Sakaguchi S (2000): Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 101, 455-458. Go to original source... Go to PubMed...
    12. Sakaguchi S (2005): Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunology 6, 345-352. Go to original source... Go to PubMed...
    13. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995): Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology 155, 1151-1164. Go to original source...
    14. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003): CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98, 1089-1099. Go to original source... Go to PubMed...
    15. Shevach EM (2002): CD4+CD25+ suppressor T cells: More questions than answers. Nature Reviews Immunology 2, 389-400. Go to original source... Go to PubMed...
    16. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L (2008): Natural killer cell-directed therapies: Moving from unexpected results to successful strategies. Nature Immunology 9, 486-494. Go to original source... Go to PubMed...
    17. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004): Foxp3 expressing CD4+ CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. Journal of Immunology 173, 1444-1453. Go to original source... Go to PubMed...
    18. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, GrubeckLoebenstein B (2003): Increase of regulatory T cells in the peripheral blood of cancer patients. Clinical Cancer Research 9, 606-612.
    19. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001): Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Research 61, 4766-4772.
    20. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Strieter RM, Dubinett SM, Sharma S (2004): Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clinical Cancer Research 10, 2891-2901. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content